#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Immune-mediated renal disorder Dilated cardiomyopathy Endocrine ophthalmopathy Obliterative bronchiolitis Ewing's sarcoma recurrent Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency Systemic sclerosis pulmonary Neuronal ceroid lipofuscinosis Rheumatoid arthritis Chronic hepatitis B Neurofibroma Hepatic angiosarcoma Marginal zone lymphoma refractory Friedreich's ataxia Canavan disease More trials…

    Learn about Rare Diseases

    Rosai-Dorfman syndrome – Trials in Disease Wiskott-Aldrich syndrome – Trials in Disease Mucopolysaccharidosis – Trials in Disease Ewing’s sarcoma recurrent – Life with Disease Indolent systemic mastocytosis – Diagnostics Methylmalonic acidaemia – Basic Information Antithrombin III deficiency – Diagnostics Angelman’s syndrome – Basic Information Leukoencephalopathy – Life with Disease Richter’s syndrome – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ascorbic Acid Bp Erenumab Corifollitropin Alfa FLUCLOXACILLIN SODIUM AMODIAQUINE Potassium Oxybate Acetic Acid, Glacial Doxazosin Mesilate Xanomeline Tartrate Baloxavir Marboxil Cobicistat Asp1570 Bemarituzumab Apocynin Sym025 Trabectedin SALICYLIC ACID Acp-017 Ipn01194 Enmetazobactam More therapies…

    Learn about Your Condition

    Oral lichen planus Bladder cancer stage II Osteomyelitis Bronchopulmonary dysplasia Infantile spasms Renal failure Diminished ovarian reserve B-cell type acute leukaemia Seasonal allergy Electrocorticogram Chordoma Huntington's disease Malignant melanoma stage IV Eclampsia Sciatica More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Primary myelofibrosis

  • Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Essential thrombocythaemia
    • Myeloproliferative neoplasm
    • Primary myelofibrosis
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Apixaban
    • Rivaroxaban
    France

  • Study on Long-Term Safety of Luspatercept for Patients with Myelodysplastic Syndrome, Beta-Thalassemia, or Myelofibrosis Who Previously Participated in Luspatercept Trials

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Thalassaemia
    • Primary myelofibrosis
    • Myelodysplastic syndrome
    Investigated Drugs:
    • Luspatercept
    Bulgaria France Germany Greece Italy The Netherlands +2

  • Study on Tasquinimod for Patients with Myelofibrosis Who Are Refractory or Intolerant to JAK2 Inhibitors

    Recruiting

    1 1 1
    Investigated Diseases:
    • Primary myelofibrosis
    • Myelofibrosis
    Investigated Drugs:
    • Tasquinimod
    Germany The Netherlands

  • Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • 2-((4S)-6-(4-Chlorophenyl)-1-Methyl-4H-Benzo[C]Isoxazolo[4,5-E]Azepin-4-Yl)Acetamide Monohydrate
    • Ruxolitinib
    Austria Belgium Czechia France Germany Italy +3

  • Study of Momelotinib and Luspatercept for Patients with Transfusion-Dependent Myelofibrosis

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Primary myelofibrosis
    Investigated Drugs:
    • Luspatercept
    • Momelotinib Dihydrochloride Monohydrate
    France Germany Italy Spain

  • Study on the Safety and Effectiveness of Navtemadlin and Ruxolitinib for Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Navtemadlin
    • Ruxolitinib
    France Italy
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!